Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Verrica, Apyx, Waste Management, and Tupperware and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ), Apyx Medical Corporation (NASDAQ:APYX ), Waste Management, Inc. (NYSE:WM ), and Tupperware Brands Corporation (NYSE:TUP ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Class Period: May 28, 2021 – May 24, 2022 Lead Plaintiff Deadline: August 5, 2022 In December 2020, Verrica submitted its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking regulatory approval of VP-102 for the treatment of molluscum. On September 20, 2021, after the market closed, Verrica announced receipt of a Complete Response Letter ("CRL") due to deficiencies at a facility of Verrica's contract manufacturer in connection with the Company's NDA. On this news, the Company's stock price fell $1.00, or 8.3%, to close at $11.03 per share on September 21, 2021, on unusually heavy trading volume. In November 2021, Verrica resubmitted the NDA for VP-102, claiming "[t]he resubmission addresses the successful resolution of inspection deficiencies" at the manufacturing facility. Then, on May 24, 2022, after the market closed, Verrica announced receipt of another Complete Response Letter regarding the VP-102 NDA citing "deficiencies identified during a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica's bulk solution drug product." On this news, the Company's shares fell $3.55, or 63.8%, to close at $2.01 per share on May 25, 2022, on unusually heavy trading volume. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For more information on the Verrica class action go to: https://bespc.com/cases/VRCA Apyx Medical Corporation (NASDAQ:APYX ) Class Period: May 12, 2021 – March 11, 2022 Lead Plaintiff Deadline: August 5, 2022 On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration ("FDA") would be posting a Medical Device Safety Communication ("MDSC") related to the Company's Advanced Energy Products. The Company further disclosed that "[b]ased on our initial interactions with the FDA, we believe the Agency's MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared ... Full story available on Benzinga.com